Hai Huang

Dr. Hai Huang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Gland Surgery
Verified
Journal Article
Open access
PDF file
ZNZhongkai Ni
Zhongkai Ni
TZTianhan Zhou
Tianhan Zhou
HFHao Fang
Hao Fang
XLXiangfeng Lin
Xiangfeng Lin
ZXZhiyu Xing
Zhiyu Xing
HHHai Huang
Hai Huang
Background: Thyroid cancer is prone to early lymph node metastasis (LNM), and patients with large volume LNM (LVLNM) tend to have a poorer prognosis. The aim of this study was to predict LVLNM in before surgery based on radiomics and deep learning (DL). Methods: A multicenter retrospective study was performed, including 854 papillary thyroid carcinoma (PTC) patients from three centers. Radiomics features were extracted. Logistic regression (LR), support vector machine (SVM), K-nearest neighbors (KNN), multi-layer perceptron (MLP), random forest (RF), ExtraTrees, extreme gradient boosting (XGBoost), and light gradient boosting machine (LightGBM) algorithms were used to construct radiomics models. AlexNet, DenseNet121, inception_v3, ResNet50, and transformer algorithms were used to construct DL models. The receiver operating characteristic (ROC) curve was employed to select the better-performing model. A combined model was then created by merging radiomics features and DL features. The least absolute shrinkage and selection operator (LASSO) method was utilized to identify metabolites and radiomics features with non-zero coefficients. The performance of the models was evaluated using area under the curve (AUC), accuracy (ACC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV), and F1-score. Results: A total of 1,357 radiomics features were extracted. Among the radiomics models, the ExtraTrees model demonstrated the optimal diagnostic capabilities with an AUC of 0.787 [95% confidence interval (CI): 0.715–0.858], and DenseNet121 DL model demonstrated the optimal diagnostic capabilities with an AUC of 0.766 (95% CI: 0.683–0.848). Furthermore, the combined model, named the Thy-DL-Radiomics model, exhibited an AUC of 0.839 (95% CI: 0.758–0.920) in the internal validation set and 0.789 (95% CI: 0.718–0.859) in the external validation set. Conclusions: A radiomics-DL features integrated model can predict LVLNM in PTC patients and provide guidance for personalized treatment.

11 May 2026 in Research Square
Verified
Preprint
Open access
PDF file
JSJinbo Shi
Jinbo Shi
ZNZhongkai Ni
Zhongkai Ni
SHShifei Huang
Shifei Huang
XLXiaowen Li
Xiaowen Li
HHHai Huang
Hai Huang
The role of adjuvant chemotherapy in stage IA (T1N0M0) pancreatic cancer remains unclear. We evaluated its survival benefit using the SEER database (2010–2022). Among 727 patients with resected stage IA disease, propensity score matching generated 241 well-balanced pairs. Chemotherapy was associated with worse overall survival (log‑rank P = 0.019) and cancer‑specific survival (P = 0.006). Subgroup analyses by age, T stage, and grade showed no benefit. A causal forest model revealed a median individual treatment effect of –2.96 months (IQR: –4.05 to 2.33 months), indicating no clinically meaningful benefit for most patients. Cross‑validation failed to confirm reliable predictive performance. Adjuvant chemotherapy was not associated with improved survival in resected stage IA pancreatic cancer, challenging its routine use and supporting a more individualized approach. Prospective validation will require multi‑institutional collaboration due to disease rarity.

12 September 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
TZTianhan Zhou
Tianhan Zhou
YZYang Zhou
Yang Zhou
ZNZhongkai Ni
Zhongkai Ni
HFHao Fang
Hao Fang
FWFan Wu
Fan Wu
HHHai Huang
Hai Huang
Accurate preoperative assessment of central lymph node metastasis (CLNM) in papillary thyroid carcinoma (PTC) remains challenging. This retrospective study was registered at ClinicalTrials.gov (NCT06725628) on December 9, 2024. A total of 934 patients with confirmed PTC who underwent cervical central lymph node dissection between January 2023 and December 2024 were included. Radiomics features were extracted and selected. Deep learning models were trained and used for automatic segmentation and classification. We developed and validated a Thy-CLNM Fusion model, which achieved an AUC of 0.862, with a sensitivity of 78.9% and a specificity of 79.3% in the validation cohort. We compared the proposed model with other models that also predict CLNM, and the results demonstrated competitive performance compared with previously reported models. Histopathological slides from 231 patients were retrospectively reviewed to provide pathological interpretability. In the CLNM low-risk group, model activation predominantly localized to hyperechoic Habitat I regions, corresponding pathologically to fibrous hyperplasia and active lymphocyte–tumor cell interactions. In the CLNM high-risk group, model attention showed dominant localization in hypoechoic Habitat II regions, which were associated with nuclear atypia, poor differentiation, reduced intercellular adhesion, and vascular invasion. The proposed model offers an additional preoperative decision-support option for CLNM risk assessment in PTC patients who are planning to undergo surgery and are being considered for central lymph node dissection.